Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 09/02/24
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to BuyZacks Investment Research • 08/15/24
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberGlobeNewsWire • 05/15/24
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024GlobeNewsWire • 05/13/24
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 04/26/24
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchGlobeNewsWire • 04/08/24
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsGlobeNewsWire • 03/26/24